Hyun Ah Yi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hyun Ah Yi has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Amy Jacobs
Department of Microbiology and Immunology, School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York 14214, United States
4 shared publications Amy Jacobs
Department of Microbiology and Immunology, State University of New York at Buffalo, Buffalo, NY 14214, United States
3 shared publications- Barbara Diaz-Rohrer
Broad Institute of MIT and Harvard, Cambridge, MA 02142
3 shared publications Chan Hee Lee
2 shared publications- Chan Hee Lee
Department of Microbiology, Chungbuk National University, Cheongju, Korea
2 shared publications - Chan Hee Lee
Department of Microbiology, Chungbuk National University, Cheongju, South Korea
2 shared publications
Latest Publications
- Open Access
Direct detection of SARS-CoV-2 RNA using high-contrast pH-sensitive dyes
The worldwide COVID-19 pandemic has had devastating effects on health, healthcare infrastructure, social structure, and economics. One of the limiting factors in containing the spread of this virus has been the lack of widespread availability of fast, inexpensive, and reliable methods for testing of individuals. Frequent screening for infected and often asymptomatic people is a cornerstone of pandemic management plans. Here, we introduce two pH sensitive ‘LAMPshade’ dyes as novel readouts in an isothermal RT-LAMP amplification assay for SARS-CoV-2 RNA. The resulting JaneliaLAMP (jLAMP) assay is robust, simple, inexpensive, has low technical requirements and we describe its use and performance in direct testing of contrived and clinical samples without RNA extraction.
Open AccessDirect detection of SARS-CoV-2 RNA using high-contrast pH-sensitive dyes
The worldwide COVID-19 pandemic has had devastating effects on health, healthcare infrastructure, social structure, and economics. One of the limiting factors in containing the spread of this virus has been the lack of widespread availability of fast, inexpensive, and reliable methods for testing of individuals. Frequent screening for infected and often asymptomatic people is a cornerstone of pandemic management plans. Here, we introduce two pH sensitive ‘LAMPshade’ dyes as novel readouts in an isothermal RT-LAMP amplification assay for SARS-CoV-2 RNA. The resulting JaneliaLAMP (jLAMP) assay is robust, simple, inexpensive, has low technical requirements and we describe its use and performance in direct testing of contrived and clinical samples without RNA extraction.
- 1 July 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (14) , 3177-3184
Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer
- 1 July 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (14) , 3177-3184
Structure-based identification of inhibitors targeting obstruction of the HIVgp41 N-heptad repeat trimer
- 4 March 2016
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 14 (3) , 283-294
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41
Background: The transmembrane subunit of the HIV envelope protein, gp41 is a vulnerable target to inhibit HIV entry. There is one fusion inhibitor T20 (brand name: Fuzeon, generic name: enfuvirtide) available by prescription. However, it has several drawbacks such as a high level of development of drug resistance, a short-half life in vivo, rapid renal clearance, low oral bioavailability, and it is only used as a salvage therapy. Therefore, investigators have been studying a variety of different modalities to attempt to overcome these limitations. Methods: Comprehensive literature searches were performed on HIV gp41, inhibition mechanisms, and inhibitors. The latest structural information was collected, and multiple inhibition strategies targeting gp41 were reviewed. Results: Many of the recent advances in inhibitors were peptide-based. Several creative modification strategies have also been performed to improve inhibitory efficacy of peptides and to overcome the drawbacks of T20 treatment. Small compounds have also been an area of intense research. There is a wide variety in development from those identified by virtual screens targeting specific regions of the protein to natural products. Finally, broadly neutralizing antibodies have also been important area of research. The inaccessible nature of the target regions for antibodies is a challenge, however, extensive efforts to develop better neutralizing antibodies are ongoing. Conclusion: The fusogenic protein, gp41 has been extensively studied as a promising target to inhibit membrane fusion between the virus and target cells. At the same time, it is a challenging target because the vulnerable conformations of the protein are exposed only transiently. However, advances in biochemical, biophysical, structural, and immunological studies are coming together to move the field closer to an understanding of gp41 structure and function that will lead to the development of novel drugs and vaccines.
- 4 March 2016
- Published by Bentham Science Publishers Ltd. in Current HIV Research
- Vol. 14 (3) , 283-294
Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41
Background: The transmembrane subunit of the HIV envelope protein, gp41 is a vulnerable target to inhibit HIV entry. There is one fusion inhibitor T20 (brand name: Fuzeon, generic name: enfuvirtide) available by prescription. However, it has several drawbacks such as a high level of development of drug resistance, a short-half life in vivo, rapid renal clearance, low oral bioavailability, and it is only used as a salvage therapy. Therefore, investigators have been studying a variety of different modalities to attempt to overcome these limitations. Methods: Comprehensive literature searches were performed on HIV gp41, inhibition mechanisms, and inhibitors. The latest structural information was collected, and multiple inhibition strategies targeting gp41 were reviewed. Results: Many of the recent advances in inhibitors were peptide-based. Several creative modification strategies have also been performed to improve inhibitory efficacy of peptides and to overcome the drawbacks of T20 treatment. Small compounds have also been an area of intense research. There is a wide variety in development from those identified by virtual screens targeting specific regions of the protein to natural products. Finally, broadly neutralizing antibodies have also been important area of research. The inaccessible nature of the target regions for antibodies is a challenge, however, extensive efforts to develop better neutralizing antibodies are ongoing. Conclusion: The fusogenic protein, gp41 has been extensively studied as a promising target to inhibit membrane fusion between the virus and target cells. At the same time, it is a challenging target because the vulnerable conformations of the protein are exposed only transiently. However, advances in biochemical, biophysical, structural, and immunological studies are coming together to move the field closer to an understanding of gp41 structure and function that will lead to the development of novel drugs and vaccines.
- 1 July 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (14) , 2853-2859
Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation
- 1 July 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 25 (14) , 2853-2859
Small molecule inhibitors of HIVgp41 N-heptad repeat trimer formation
- Open Access
- 20 April 2015
- Published by Springer Nature in Nature Chemistry
- Vol. 7 (5) , 438-446
Functionalization of cobalt porphyrin–phospholipid bilayers with his-tagged ligands and antigens
Methods to attach polypeptides to lipid bilayers are often indirect and ineffective, and can represent a substantial bottleneck in the formation of functionalized lipid-based materials. Although the polyhistidine tag (his-tag) has been transformative in its simplicity and efficacy in binding to immobilized metals, the successful application of this approach has been challenging in physiological settings. Here we show that lipid bilayers containing porphyrin–phospholipid conjugates that are chelated with cobalt, but not with other metals, can effectively capture his-tagged proteins and peptides. The binding follows a Co(II) to Co(III) transition and occurs within the sheltered hydrophobic bilayer, resulting in an essentially irreversible attachment in serum or in a million fold excess of competing imidazole. Using this approach we anchored homing peptides into the bilayer of preformed and cargo-loaded liposomes to enable tumour targeting without disrupting the bilayer integrity. As a further demonstration, a synthetic protein fragment derived from the human immunodeficiency virus was bound to immunogenic liposomes for potent antibody generation for an otherwise non-antigenic peptide.
- 20 April 2015
- Published by Springer Nature in Nature Chemistry
- Vol. 7 (5) , 438-446
Open AccessFunctionalization of cobalt porphyrin–phospholipid bilayers with his-tagged ligands and antigens
Methods to attach polypeptides to lipid bilayers are often indirect and ineffective, and can represent a substantial bottleneck in the formation of functionalized lipid-based materials. Although the polyhistidine tag (his-tag) has been transformative in its simplicity and efficacy in binding to immobilized metals, the successful application of this approach has been challenging in physiological settings. Here we show that lipid bilayers containing porphyrin–phospholipid conjugates that are chelated with cobalt, but not with other metals, can effectively capture his-tagged proteins and peptides. The binding follows a Co(II) to Co(III) transition and occurs within the sheltered hydrophobic bilayer, resulting in an essentially irreversible attachment in serum or in a million fold excess of competing imidazole. Using this approach we anchored homing peptides into the bilayer of preformed and cargo-loaded liposomes to enable tumour targeting without disrupting the bilayer integrity. As a further demonstration, a synthetic protein fragment derived from the human immunodeficiency virus was bound to immunogenic liposomes for potent antibody generation for an otherwise non-antigenic peptide.
- 3 February 2015
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 54 (8) , 1681-1693
The Membrane Proximal External Regions of gp41 from HIV-1 Strains HXB2 and JRFL Have Different Sensitivities to Alanine Mutation
The transmembrane subunit (gp41) of the HIV envelope protein complex (Env) mediates the viral fusion step of HIV entry. The membrane proximal external region (MPER), one of the functional domains of gp41, has been the focus of a great deal of research because it is a target for neutralizing antibodies. In this study, we examined 23 amino acid residues in the MPER (660–683) in both a CXCR4 coreceptor-utilizing strain (HXB2) and a CCR5-utilizing strain (JRFL) by alanine scanning mutagenesis. Despite the high degree of gp41 sequence conservation, the effects of alanine mutation in the MPER were different between the two strains. Most mutations in HXB2 had fusogenicity and protein expression levels not less than 50% of that of the wild type in the case of cell–cell fusion. However, ∼30% of the mutants in HXB2 showed a severe defect in fusogenicity in viral entry. Mutations in the MPER of strain JRFL had more dramatic effects than that in HXB2 in cell–cell fusion and viral entry. The fact that there are large differences in the effects of mutation between two strains suggests the potential for the interaction of the MPER with nonconserved sequences such as the fusion peptide and/or other NHR domains as well as potential long-range structural effects on the conformational changes that occur with the Env complex during membrane fusion.
- 3 February 2015
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 54 (8) , 1681-1693
The Membrane Proximal External Regions of gp41 from HIV-1 Strains HXB2 and JRFL Have Different Sensitivities to Alanine Mutation
The transmembrane subunit (gp41) of the HIV envelope protein complex (Env) mediates the viral fusion step of HIV entry. The membrane proximal external region (MPER), one of the functional domains of gp41, has been the focus of a great deal of research because it is a target for neutralizing antibodies. In this study, we examined 23 amino acid residues in the MPER (660–683) in both a CXCR4 coreceptor-utilizing strain (HXB2) and a CCR5-utilizing strain (JRFL) by alanine scanning mutagenesis. Despite the high degree of gp41 sequence conservation, the effects of alanine mutation in the MPER were different between the two strains. Most mutations in HXB2 had fusogenicity and protein expression levels not less than 50% of that of the wild type in the case of cell–cell fusion. However, ∼30% of the mutants in HXB2 showed a severe defect in fusogenicity in viral entry. Mutations in the MPER of strain JRFL had more dramatic effects than that in HXB2 in cell–cell fusion and viral entry. The fact that there are large differences in the effects of mutation between two strains suggests the potential for the interaction of the MPER with nonconserved sequences such as the fusion peptide and/or other NHR domains as well as potential long-range structural effects on the conformational changes that occur with the Env complex during membrane fusion.
- 1 July 2013
- Published by Elsevier in Journal of Virological Methods
- Vol. 191 (1) , 16-23
Development of a new cell culture-based method and optimized protocol for the detection of enteric viruses
- 1 July 2013
- Published by Elsevier in Journal of Virological Methods
- Vol. 191 (1) , 16-23
Development of a new cell culture-based method and optimized protocol for the detection of enteric viruses
- Open Access
- 26 April 2013
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 52 (20) , 3552-3563
Significant Differences in Cell–Cell Fusion and Viral Entry between Strains Revealed by Scanning Mutagenesis of the C-Heptad Repeat of HIV gp41
The transmembrane subunit, gp41, of HIV envelope mediates the viral fusion step of entry into the host cell. The protein consists of an extracellular domain, a transmembrane domain, and a cytoplasmic tail. The extracellular domain contains a fusion peptide, an N-terminal heptad repeat (NHR), a loop region, a C-terminal heptad repeat (CHR), and a membrane-proximal external region (MPER). For this study we examined each amino acid in the CHR (623-659), by alanine scanning mutagenesis in two HIV strains; one CCR5-utilizing (strain JRFL) and one CXCR4-utilizing (strain HXB2). We studied the functional importance of each amino acid residue by measuring mutational effects in both cell-cell fusion and viral entry and assessing envelope expression and gp120/gp41 proteolytic processing. The transmembrane subunit of HIV envelope, gp41, is very sensitive to subtle changes, like alanine substitution, which severely affect envelope function at multiple sites. Two important general findings are apparent when the entire data set from this study is taken into account: 1) strain HXB2 is much more stable to mutagenesis than is strain JRFL and 2) viral entry is much more stable to mutagenesis than is cell-cell fusion. These findings strengthen our notion that gp41 is a vulnerable target for therapeutic and prophylactic intervention. Further structural studies to gain a full understanding of the intermediate states that drive HIV membrane fusion are imperative.
- 26 April 2013
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 52 (20) , 3552-3563
Open AccessSignificant Differences in Cell–Cell Fusion and Viral Entry between Strains Revealed by Scanning Mutagenesis of the C-Heptad Repeat of HIV gp41
The transmembrane subunit, gp41, of HIV envelope mediates the viral fusion step of entry into the host cell. The protein consists of an extracellular domain, a transmembrane domain, and a cytoplasmic tail. The extracellular domain contains a fusion peptide, an N-terminal heptad repeat (NHR), a loop region, a C-terminal heptad repeat (CHR), and a membrane-proximal external region (MPER). For this study we examined each amino acid in the CHR (623-659), by alanine scanning mutagenesis in two HIV strains; one CCR5-utilizing (strain JRFL) and one CXCR4-utilizing (strain HXB2). We studied the functional importance of each amino acid residue by measuring mutational effects in both cell-cell fusion and viral entry and assessing envelope expression and gp120/gp41 proteolytic processing. The transmembrane subunit of HIV envelope, gp41, is very sensitive to subtle changes, like alanine substitution, which severely affect envelope function at multiple sites. Two important general findings are apparent when the entire data set from this study is taken into account: 1) strain HXB2 is much more stable to mutagenesis than is strain JRFL and 2) viral entry is much more stable to mutagenesis than is cell-cell fusion. These findings strengthen our notion that gp41 is a vulnerable target for therapeutic and prophylactic intervention. Further structural studies to gain a full understanding of the intermediate states that drive HIV membrane fusion are imperative.
- 1 January 2012
- Published by Elsevier in Microbial Pathogenesis
- Vol. 52 (1) , 25-30
Inhibition of HIV entry by extracellular glucuronoxylomannan of Cryptococcus neoformans
- 1 January 2012
- Published by Elsevier in Microbial Pathogenesis
- Vol. 52 (1) , 25-30
Inhibition of HIV entry by extracellular glucuronoxylomannan of Cryptococcus neoformans
- 15 July 2011
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 50 (32) , 6966-6972
Permanent Inhibition of Viral Entry by Covalent Entrapment of HIV gp41 on the Virus Surface
HIV entry occurs by concerted conformational changes in the envelope protein complex on the surface of the virus. This complex is made up of a trimer of heterodimers of two subunits: surface subunit, gp120, and transmembrane subunit, gp41. Conformational changes in the envelope complex allow gp41 to mediate membrane fusion leading to exposure of two gp41 regions: N-heptad repeat (NHR) and C-heptad repeat (CHR). Peptides from the NHR or the CHR have been found to inhibit HIV entry. Herein we show that we can covalently inhibit HIV viral entry by permanently trapping the gp41 intermediate on the virus surface using a covalently reactive group on inhibitory peptides. This is evidence showing that vulnerable conformational intermediates exist transiently during HIV viral entry, and the details presented herein will facilitate development of envelope as a target for therapeutics and potential chemopreventive agents that could disable the virus before contact with the host cell.
- 15 July 2011
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 50 (32) , 6966-6972
Permanent Inhibition of Viral Entry by Covalent Entrapment of HIV gp41 on the Virus Surface
HIV entry occurs by concerted conformational changes in the envelope protein complex on the surface of the virus. This complex is made up of a trimer of heterodimers of two subunits: surface subunit, gp120, and transmembrane subunit, gp41. Conformational changes in the envelope complex allow gp41 to mediate membrane fusion leading to exposure of two gp41 regions: N-heptad repeat (NHR) and C-heptad repeat (CHR). Peptides from the NHR or the CHR have been found to inhibit HIV entry. Herein we show that we can covalently inhibit HIV viral entry by permanently trapping the gp41 intermediate on the virus surface using a covalently reactive group on inhibitory peptides. This is evidence showing that vulnerable conformational intermediates exist transiently during HIV viral entry, and the details presented herein will facilitate development of envelope as a target for therapeutics and potential chemopreventive agents that could disable the virus before contact with the host cell.